Scaling Hope: Growth Of The Allogeneic Cell Therapy Sector

By Anshul Mangal, President of Project Farma & Precision for Medicine and John Khoury, Executive Vice President of Project Farma

The advanced therapy landscape is rapidly evolving with a number of therapies advancing through clinical trials and several products receiving approval. Six autologous CAR-T cell immunotherapy products have been approved by the FDA since 2017. However, the elaborate process of drawing and modifying patient cells, high level of customization, and lengthy manufacturing process associated with autologous therapies stifle widespread adoption. Cell therapies ultimately require a streamlined, affordable process to be positioned as a viable first-line treatment option.

Allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. By utilizing cells from healthy donors which are then genetically modified and stored in large batches, allogeneic cell therapies enable an accelerated treatment timeline and larger-scale preparation, helping to reduce costs and increase accessibility.

Anshul Mangal, President of Project Farma & Precision for Medicine, and John Khoury, Executive Vice President of Project Farma, discuss the growth of the allogeneic cell therapy sector and how the modality is poised to revolutionize treatment for numerous diseases.